At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Levocetirizine dihydrochloride (Xyzal) +1 moredrug
Likely dose
Levocetirizine dihydrochloride (Xyzal) 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study
In Brief
A Phase 4 clinical trial evaluating Levocetirizine dihydrochloride (Xyzal) and placebo for Atopic Dermatitis and Pruritus. Completed, enrolled 40 participants across 1 site.
Detailed Summary
It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra. It will be a welcome addition to our treatment armamentarium if a drug such as Xyzal can control pruritus associated with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Pruritus
CountriesUnited States
CollaboratorsUCB Pharma
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedApr 2009
Primary CompletionJan 2010
TodayJul 2026
First PostedApr 20, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.2 years ago
Interventions
Levocetirizine dihydrochloride (Xyzal)drug
One tablet 5 mg taken orally at night for 28 days
placebodrug
One tablet taken orally at night for 28 days